Kefah Mokbel, Chair of Breast Cancer Surgery at London Breast Institute and Honorary Professor of Medicine at Cardiff University School of Medicine, shared a post on LinkedIn:
“New Evidence Shows That Adjuvant Chemotherapy Improves Survival in T1bN0 Triple Negative Breast Cancer.
This meta-analysis shows that adjuvant chemotherapy is associated with higher survival in patients with T1bN0 triple-negative breast cancer (TNBC). This finding reinforces the importance of individualized treatment planning in early-stage TNBC and highlights the potential benefit of systemic therapy even in traditionally low-burden disease.
Clinicians should consider these data when discussing adjuvant therapy options with patients and in shared decision-making. Continued research and multidisciplinary collaboration are essential to further refine strategies for optimizing outcomes in TNBC across all stages.
No survival benefits were observed with chemotherapy in patients with T1aN0 TNBC.”
Title: Benefit of adjuvant chemotherapy in patients with T1a-bN0, triple-negative breast cancer – A systematic review and meta-analysis
Authors: Christina M.S. Hassing, Carsten Bogh Juhl, Tove Holst Filtenborg Tvedskov, Dorte Lisbet Nielsen, Ann Søegaard Knoop, Niels Thorndahl Kroman, Anne-Vibeke Lænkholm, Iben Kümler
Read The Full Article
Other articles about TNBC on OncoDaily.